Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03517436 · ClinicalTrials.gov registry record · NA

ExCEED: CENTERA THV System in Intermediate Risk Patients Who Have Symptomatic, Severe, Calcific, Aortic Stenosis

A NA study of Aortic Valve Stenosis, sponsored by Edwards Lifesciences.

Active
Registry status
NA
Development phase
101
Enrollment target
20
Study locations

NCT03517436: Active NA study of Aortic Valve Stenosis, sponsored by Edwards Lifesciences.

NCT03517436 is a NA study of Aortic Valve Stenosis that is active but no longer recruiting, run by Edwards Lifesciences. The registered enrollment target is 101 participants, below the 1,040-participant average among 30 other Aortic Valve Stenosis trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03517436, a NA study of Aortic Valve Stenosis, is active but no longer recruiting, sponsored by Edwards Lifesciences.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
101 participants
Enrollment target
20
Study locations

Study Summary

This study will monitor the safety and valve performance of the Edwards CENTERA Transcatheter Heart Valve (THV) System in patients with symptomatic, severe, calcific aortic stenosis who are at intermediate operative risk for surgical aortic valve replacement (SAVR).

Primary Outcome

Number of participants that died

Conditions Studied

Interventions

  • DEVICE TAVR with CENTERA THV

Study Locations (20)

California

  • Cedars-Sinai Medical Center - Los Angeles
  • Stanford University Medical Center - Stanford

Kansas

  • University of Kansas Health System - Kansas City
  • Cardiovascular Research Institute of Kansas - Wichita

Pennsylvania

  • University of Pennsylvania - Philadelphia
  • Allegheny - Singer Research Institute - Pittsburgh

Texas

  • Baylor Heart and Vascular Hospital - Dallas
  • The University of Texas Health Science Center at Houston - Houston

Colorado

  • UC Health Northern Colorado (Medical Center of the Rockies) - Loveland

District of Columbia

  • Washington Hospital Center - Washington D.C.

Florida

  • Sarasota Memorial Hospital - Sarasota

Georgia

  • Emory University - Atlanta

Trial Details

FieldValue
Enrollment Target 101 participants
Start Date 2018-09-18
Est. Completion 2030-07
Phase NA
Edwards Lifesciences

57 total trials

What the registry record for NCT03517436 still lists

NCT03517436 is an interventional study that assigns participants to a tested intervention. The registered 101 participants enrollment target is mid-sized for trials with a published cap, below the 1,040-participant average among 30 other Aortic Valve Stenosis trials with a reported enrollment target (90% lower).

The record links to 1 condition, with Aortic Valve Stenosis appearing as the primary indexed condition, and to 1 intervention - of which TAVR with CENTERA THV is the first listed.

NCT03517436 names 20 study sites across 16 states, led by California, Kansas, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT03517436 about?

NCT03517436 is a clinical study titled "ExCEED: CENTERA THV System in Intermediate Risk Patients Who Have Symptomatic, Severe, Calcific, Aortic Stenosis". This study will monitor the safety and valve performance of the Edwards CENTERA Transcatheter Heart Valve (THV) System in patients with symptomatic, severe, calcific aortic stenosis who are at intermediate operative risk for surgical aortic valve replacement (SAVR).

What is the current status of trial NCT03517436?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 101 participants. The study started on 2018-09-18. Estimated completion is 2030-07.

What conditions does trial NCT03517436 study?

This clinical trial studies the following conditions: Aortic Valve Stenosis.

What interventions are being tested in trial NCT03517436?

The interventions under investigation include: TAVR with CENTERA THV (DEVICE).

Who is sponsoring clinical trial NCT03517436?

This trial is sponsored by Edwards Lifesciences, which has 57 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03517436 being conducted?

This trial has 20 study locations across California, Colorado, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Aortic Valve Stenosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03517436's enrollment target sits among peer trials

101 19th of 30 higher than 12 of 30 other Aortic Valve Stenosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Aortic Valve Stenosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04033497 · 101 participants · NA

    Treatment Response Assessment Maps to Delineate Necrosis From Tumor After Stereotactic Radiation in Brain Metastases

  • NCT05111574 · 101 participants · Phase 2

    Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery

  • NCT05984680 · 101 participants

    COPD Care Pathway Among Patients With Cancer

  • NCT06266299 · 101 participants · Phase 1

    A Study of KK2269 in Adult Participants With Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03517436, the US trial registry maintained by the National Library of Medicine. NCT03517436 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.